320 related articles for article (PubMed ID: 35667066)
1. Cannabis-Based Products for Chronic Pain : A Systematic Review.
McDonagh MS; Morasco BJ; Wagner J; Ahmed AY; Fu R; Kansagara D; Chou R
Ann Intern Med; 2022 Aug; 175(8):1143-1153. PubMed ID: 35667066
[TBL] [Abstract][Full Text] [Related]
2. Cannabis-based medicines for chronic neuropathic pain in adults.
Mücke M; Phillips T; Radbruch L; Petzke F; Häuser W
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD012182. PubMed ID: 29513392
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis.
Black N; Stockings E; Campbell G; Tran LT; Zagic D; Hall WD; Farrell M; Degenhardt L
Lancet Psychiatry; 2019 Dec; 6(12):995-1010. PubMed ID: 31672337
[TBL] [Abstract][Full Text] [Related]
4. Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials.
Wang L; Hong PJ; May C; Rehman Y; Oparin Y; Hong CJ; Hong BY; AminiLari M; Gallo L; Kaushal A; Craigie S; Couban RJ; Kum E; Shanthanna H; Price I; Upadhye S; Ware MA; Campbell F; Buchbinder R; Agoritsas T; Busse JW
BMJ; 2021 Sep; 374():n1034. PubMed ID: 34497047
[TBL] [Abstract][Full Text] [Related]
5. The effects of cannabis, cannabinoids, and their administration routes on pain control efficacy and safety: A systematic review and network meta-analysis.
Rabgay K; Waranuch N; Chaiyakunapruk N; Sawangjit R; Ingkaninan K; Dilokthornsakul P
J Am Pharm Assoc (2003); 2020; 60(1):225-234.e6. PubMed ID: 31495691
[TBL] [Abstract][Full Text] [Related]
6. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
[TBL] [Abstract][Full Text] [Related]
7. A Multicriteria Decision Analysis Comparing Pharmacotherapy for Chronic Neuropathic Pain, Including Cannabinoids and Cannabis-Based Medical Products.
Nutt DJ; Phillips LD; Barnes MP; Brander B; Curran HV; Fayaz A; Finn DP; Horsted T; Moltke J; Sakal C; Sharon H; O'Sullivan SE; Williams T; Zorn G; Schlag AK
Cannabis Cannabinoid Res; 2022 Aug; 7(4):482-500. PubMed ID: 33998895
[No Abstract] [Full Text] [Related]
8. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT
J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of cannabis-based medications compared to placebo for the treatment of chronic neuropathic pain: a systematic review with meta-analysis.
Sainsbury B; Bloxham J; Pour MH; Padilla M; Enciso R
J Dent Anesth Pain Med; 2021 Dec; 21(6):479-506. PubMed ID: 34909469
[TBL] [Abstract][Full Text] [Related]
10. Approved cannabinoids for medical purposes - Comparative systematic review and meta-analysis for sleep and appetite.
Spanagel R; Bilbao A
Neuropharmacology; 2021 Sep; 196():108680. PubMed ID: 34181977
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: A systematic review of randomized controlled studies].
Petzke F; Enax-Krumova EK; Häuser W
Schmerz; 2016 Feb; 30(1):62-88. PubMed ID: 26830780
[TBL] [Abstract][Full Text] [Related]
12. Long-term and serious harms of medical cannabis and cannabinoids for chronic pain: a systematic review of non-randomised studies.
Zeraatkar D; Cooper MA; Agarwal A; Vernooij RWM; Leung G; Loniewski K; Dookie JE; Ahmed MM; Hong BY; Hong C; Hong P; Couban R; Agoritsas T; Busse JW
BMJ Open; 2022 Aug; 12(8):e054282. PubMed ID: 35926992
[TBL] [Abstract][Full Text] [Related]
13. The therapeutic potential of cannabis and cannabinoids.
Grotenhermen F; Müller-Vahl K
Dtsch Arztebl Int; 2012 Jul; 109(29-30):495-501. PubMed ID: 23008748
[TBL] [Abstract][Full Text] [Related]
14. The anti-inflammatory and analgesic effects of formulated full-spectrum cannabis extract in the treatment of neuropathic pain associated with multiple sclerosis.
Maayah ZH; Takahara S; Ferdaoussi M; Dyck JRB
Inflamm Res; 2020 Jun; 69(6):549-558. PubMed ID: 32239248
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: A systematic review and meta-analysis.
Velayudhan L; McGoohan K; Bhattacharyya S
PLoS Med; 2021 Mar; 18(3):e1003524. PubMed ID: 33780450
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
Rice J; Cameron M
Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025
[TBL] [Abstract][Full Text] [Related]
17. Pilot clinical and pharmacokinetic study of Δ9-Tetrahydrocannabinol (THC)/Cannabidiol (CBD) nanoparticle oro-buccal spray in patients with advanced cancer experiencing uncontrolled pain.
Clarke S; Butcher BE; McLachlan AJ; Henson JD; Rutolo D; Hall S; Vitetta L
PLoS One; 2022; 17(10):e0270543. PubMed ID: 36240167
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
